SurgePays Announces Strategic Partnership With SIN PIN

SurgePays, Inc. (NASDAQ:SURG) ("SurgePays" or the "Company"), a technology and telecom company focused on the underbanked and underserved communities, announced today that it has entered into a distribution agreement

SurgePays, Inc. (NASDAQ:SURG) (“SurgePays” or the “Company”), a technology and telecom company focused on the underbanked and underserved communities, announced today that it has entered into a distribution agreement with SIN PIN, a telecommunications service provider to immigrant communities in the US, which we believe will drive wireless subscriber growth in the Hispanic community.

 

President of SurgePays, Jeremy Gies, said, “SIN PIN provides us thousands of distribution points to service immigrant populations beyond the traditional convenience store. We believe these stores represent a fantastic opportunity to increase our wireless subscriber base significantly. With over 150 team members working at our operations center in El Salvador, we are uniquely positioned to provide excellent store and customer support for Spanish-speaking customers. We are planning on making an impact in the Hispanic wireless market.”

The distribution agreement provides SIN PIN integrated access to the SurgePays software platform to activate prepaid wireless subscribers and allow consumers to apply for the Affordable Connectivity Program (ACP) at thousands of retail locations.  

“We are very happy to work with a strong partner like SurgePays. This strategic partnership with SurgePays will enable SIN PIN to bring cost savings prepaid wireless and the ACP to our customers and help enrich their lives,” said Alexander Barnes, COO of SIN PIN.

Total
0
Shares
Related Posts
Read More

FDA Granted Mesoblast Regenerative Medicine Advanced Therapy Designation granted For Rexlemestrocel-L In Chronic Low Back Pain

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the United States Food and Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent

MESO